Immunologic "vaccination" for the prevention of autoimmune diabetes (type 1A).
Diabetes type 1A is an autoimmune condition characterized by lymphocytic infiltration of islets and selective destruction of insulin-secreting beta-cells. Numerous investigators have prevented diabetes in animal models with a variety of antigens and routes of administration. It is also now possible to identify high-risk individuals even before the appearance of autoantibodies. These advances have created the opportunity to design and begin human prevention trials. This review focuses on a variety of immunomodulatory approaches (including administration of adjuvants, autoantigens, T-cells, T-cell receptors, and DNA) that we have collectively termed immunologic "vaccination." In addition, we discuss the potential benefits and dangers of these approaches and issues relating to the design of human trials.
Simone
E A
EA
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver 80262.
Wegmann
D R
DR
Eisenbarth
G S
GS
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D019264:Adoptive Transfer; D001324:Autoantigens / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D012107:Research Design; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA
D000276:Adjuvants, Immunologic; D001324:Autoantigens; D011948:Receptors, Antigen, T-Cell; D019444:Vaccines, DNA